Announcements Trials
Browse Landscape

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 39Observational 2Expanded_access 1

Sponsor

Cancer Type

Breast 2

Conditions

HER2-positive Breast Cancer 2

Interventions

Surveys and Questionnaires 529Blood Specimen Collection 405Surgical Procedures, Operative 151Interviews as Topic 131Radiotherapy 130Observation 122Drug Therapy 122Magnetic Resonance Spectroscopy 104Biopsy 103Specimen Handling 70Data Collection 70Neoadjuvant Therapy 65Immunohistochemistry 64Magnetic Resonance Imaging 61Immune Checkpoint Inhibitors 58Watchful Waiting 51Immunotherapy 51Bevacizumab 49Positron Emission Tomography Computed Tomography 46Ultrasonography 44Liquid Biopsy 41Hematologic Tests 41Tomography, X-Ray Computed 40Therapeutics 40Radiosurgery 40Colonoscopy 40pembrolizumab 37Hepatectomy 37Gene Expression Profiling 36High-Energy Shock Waves 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Observational × neratinib × Clear all
NCT07019272 2025-06-13

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

Hebei Medical University Fourth Hospital

Not yet recruiting
170 enrolled
Breast

HER2-positive Breast Cancer

NCT06693024 2024-11-20

NeraHER2

Peking University People's Hospital

Recruiting
2,806 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡